Number	COMPETENCY The student should be able to	Domain K/S/A/C	Level K/KH/S H/P
Topic: Acne		Number of	competencies:(03
DR1.1	Enumerate the causative and risk factors of acne	K	К
DR1.2	Identify and grade the various common types of acne	S	SH
DR1.3	Describe the treatment and preventive measures for various kinds of acne	K	K
	T	opic: Vitiligo	
DR2.1	Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance	K	КН
DR2.2	Describe the treatment of vitiligo	K	K
	Topic: Papulo squamous disorders		Number of co
DR3.1	Identify and distinguish psoriatic lesions from other causes	К	SH
DR3.2	Demonstrate the grattage test	S	SH

DR3.3	Enumerate the indications for and describe the various modalities of treatment of psoriasis including topical, systemic and phototherapy	К	KH
	Topic: Lichen Planus		Number of compe
DR4.1	Identify and distinguish lichen planus lesions from other causes	S	SH
DR4.2	Enumerate and describe the treatment modalities for lichen planus	К	КН
DD 5.1		oic: Scabies	
DR5.1	Describe the etiology, microbiology, pathogenesis, natural history, clinical features, presentations and complications of scabies in adults and children	К	КН

DR5.2	Identify and differentiate scabies from other lesions in adults and children	S	SH
DR5.3	Enumerate and describe the pharmacology, administration and adverse reaction of pharmacotherapies for scabies	К	КН
	To	pic: Pediculosis	
DR6.1	Describe the etiology pathogenesis and diagnostic features of pediculosis in adults and children	К	KH
DR6.2	Identify and differentiate pediculosis from other skin lesions in adults and children	Ø	SH

	Тор	oic: Fungal Inf	ections
DR7.1	Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of dermatophytes in adults and children	К	КН
DR7.2	Identify Candida species in fungal scrapings and KOH mount	S	SH
DR7.3	Describe the pharmacology and action of antifungal (systemic and topical) agents. Enumerate side effects of antifungal therapy	K K	KH
		pic: Viral infec	
DR8.1	Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of common viral infections of the skin in adults and children	К	KH

DR8.2	Identify and distinguish herpes simplex and herpes labialis from other skin lesions			
		S	SH	
DR8.3	Identify and distinguish herpes zoster and varicella from other skin lesions			
		S	SH	
OR8.4	Identify and distinguish viral warts from other skin lesions			
		S	SH	
OR8.5	Identify and distinguish molluscum contagiosum from other skin lesions			
		S	SH	

DR8.6	Enumerate the indications, describe the procedure and perform a Tzanck smear		
		S	SH
DR8.7	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for common viral illnesses of the skin	К	КН
	To	pic: Leprosy	<u> </u>
DR9.1	Classify, describe the epidemiology, etiology, microbiology, pathogenesis, clinical presentations and diagnostic features of Leprosy	K	КН
DR9.2	Demonstrate (and classify based on) the clinical features of leprosy including an appropriate neurologic examination		

		S	SH
DR9.3	Enumerate the indications and observe the performance of a slit skin smear in patients with leprosy	S	SH
DR9.4	Enumerate, describe and identify lepra reactions and supportive measures and therapy of lepra reactions		
		S	SH
DR9.5	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for various classes of leprosy based on national guidelines		
		S	SH
DR9.6	Describe the treatment of Leprosy based on the WHO guidelines	S	SH
DR9.7	Enumerate and describe the complications of leprosy and its management, including understanding disability and stigma.	K	КН

		in Councille	Transpitted Dies
DR10.1	Identify and classify syphilis based on the presentation and clinical manifestations		Transmitted Dise
DR10.2	Identify spirochete in a dark ground microscopy	S	SH
DR10.3	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for syphilis	K	KH
DR10.4	Describe the prevention of congenital syphilis	К	КН
DR10.5	Counsel in a non-judgemental and empathetic manner patients or prevention of sexually transmitted disease	C	SH
DR10.6	Describe the etiology, diagnostic and clinical features of non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	K	KH

DR10.7	Identify and differentiate based on the clinical features non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	S	SH
DR10.8	Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	K	KH

DR10.9	Describe the syndromic approach to ulcerative sexually transmitted disease	К	KH
DR10.10	Describe the etiology, diagnostic and clinical features and management of gonococcal and non-gonococcal urethritis		
		К	КН
R10.11	Describe the etiology, diagnostic and clinical features and management of vaginal discharge	К	KH
	Тор	ic: HIV	
DR11.1	Describe the etiology, pathogenesis and clinical features of the dermatologic manifestations of HIV and its complications including opportunistic infections	K	КН

DR11.2	Identify and distinguish the dermatologic manifestations of HIV, its complications, opportunistic infections and adverse reactions	S	SH
DR11.3	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for dermatologic lesions in HIV	K	КН
	Tor	ic: Dermatitis	and Eczema
DR12.1	Describe the aetiopathogenesis of eczema	K	KH
DR12.2	Identify eczema and differentiate it from lichenification and changes of aging		

DR12.1 Describe the aetiopathogenesis of eczema K KH

DR12.2 Identify eczema and differentiate it from lichenification and changes of aging S SH

DR12.3 Classify and grade eczema K KH

DR12.4 Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema

112.7	Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other skin lesions	S	SH
		S	SH
DR12.6	Identify and distinguish exfoliative dermatitis from other skin lesions		
DD12.5			
		S	SH
2101 2 10	erythroderma. Discuss the treatment		
DR12.5	Define erythroderma. Enumerate and identify the causes of		
		K	КН

DR13.2	Demonstrate the Tzanck test, nikolsky sign and bulla spread sign	S	SH
DR13.3	Calculate the body surface area of involvement of vesiculobullous lesions	S	SH
Tonic: Urti	_l caria Angioedema	Number of	competencies: (0
DR14.1	Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema	К	КН
DR14.2	Identify and distinguish urticarial from other skin lesions	S	SH
DR14.3	Identify and distinguish urticarial from other skin lesions	S	SH
DR14.4	Identify and distinguish angioedema from other skin lesions		
		S	SH

	I	1	1
DR14.5	Enumerate the indications and describe the pharmacology	K	КН
Topic: Pyo	l derma	Number of c	ompetencies: (0
DR15.1	Identify and distinguish folliculitis impetigo and carbuncle from other skin lesions	S	SH
DR15.2	Identify staphylococcus on a gram stain	S	SH
DR15.3	Enumerate the indications and describe the pharmacology, indications and adverse reactions of topical and systemic drugs used in treatment of pyoderma	K	КН

1	1	1	
DR15.4	Enumerate the indications for surgical referral	S	SH
Tamia, Cal	lawa Maasulaa diasaa	Number of	
DR16.1	Identify and distinguish skin lesions of SLE	S Number of C	SH SH
DICTO.T	dentify and distinguish skin resions of SEE		511
DR16.2	Identify and distinguish Raynaud's phenomenon	S	SH
Topic: Nut	ritional Deficiencies and Skin	Number of	competencies: (0
DR17.1	Enumerate and identify the cutaneous findings in vitamin A	K/S	SH
	deficiency		
DR17.2	Enumerate and describe the various skin changes in Vitamin B	K	KH
	complex deficiency		
DD 17. 4		T7	1711
DR17.4	Enumerate and describe the various changes in Vitamin C deficiency	K	KH
	delicione		

DR17.4	Enumerate and describe the various changes in Zinc deficiency	K	KH
Topic: Sys	stemic diseases and the skin	Number of	competencies:(0)
DR18.1	Enumerate the cutaneous features of Type 2 diabetes	К	К
DR18.2	Enumerate the cutaneous features of hypo/hyper-thyroidism	К	К

Column C: K- Knowledge, S – Skill, A - Attitude / professionalism, C- Com Column D: K – Knows, KH - Knows How, SH - Shows how, P- performs in Column H: If entry is P: indicate how many procedures mu

Number	COMPETENCY The student should be able to	Domain K/S/A/C	Level K/KH/SH/P
AN4.2	Describe structure & function of skin with its appendages	K	КН
AN4.4	Describe modifications of deep fascia with its functions	K	КН
AN4.5	Explain principles of skin incisions	K	KH
PA34.1	Describe the risk factors, pathogenesis, pathology and natural history of squamous cell carcinoma of the skin	K	КН

PA34.2	Describe the risk factors, pathogenesis, pathology and natural history of basal cell carcinoma of the skin	K	КН
PA34.3	Describe the distinguishing features between a nevus and melanoma. Describe the etiology, pathogenesis, risk factors, morphology, clinical features and metastases of melanoma	K	КН
PA34.4	Identify, distinguish and describe common tumors of the skin	S	SH

			1
MI4.3	Describe the etio-pathogenesis of Skin and soft tissue infections and discuss the clinical course, and the laboratory diagnosis.	K	KH
MI7.2	Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures, wherever relevant.	K	KH
PH1.46	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antileprotic drugs	K	КН
PH1.57	Describe drugs used in skin disorders	K	KH
PE31.4	Identify Atopic dermatitis and manage	S	SH

Core Y/N	Objectives	Date
) Number	r of procedures that require certificaion:(NIL)	
Y	A. At the end of the session the phase III student must be able to	01.04.2020
	enumerate the causative factors in the etiology of acne.	
	B. At the end of the session the phase III student must be able to	
	enumerate the risk factors of acne.	
Y	A. At the end of the session the phase III student must be able to	01.04.2020
	identify the various morphological presentations of acne.	
	B. At the end of the session the phase III student must be able to	
	enumerate the risk factors of acne.	
	C. At the end of the session the phase III student must be able to grade	
	acne	
Y	A. At the end of the session the phase III student must be able to	01.04.2020
	describe the various treatment modalities (topical, oral and physical) for	
	the management of acne.	
	B. At the end of the session the phase III student must be able to	
	describe the various preventive measures for acne.	6 1 41 4
X7	<u> </u>	of procedures that r
Y	A. At the end of the session the phase III student must be able to	04.04.2020
	identify the clinical lesions of Vitiligo. B. At the end of the session the phase III student must be able to	
	enumerate different causes of hypopigmented lesions.	
	C. At the end of the session the phase III student must be able to	
	differentiate vitiligo from other causes of hypopigmented lesions.	
	differentiate vitingo from other eduses of hypopigmented lesions.	
Y	A.At the end of the session the phase III student must be able to	04.04.2020
	describe the medical treatment of Vitiligo	
	B.At the end of the session the phase III student must be able to	
	describe the use of phototherapy in treatment of Vitiligo	
	C.At the end of the session the phase III student must be able to	
	enumerate the various surgical modalities for the treatment of vitiligo	
mpetencies:(03)	Number of procedures that require certificaion:(NIL)	· · · · · · · · · · · · · · · · · · ·
Y	A.At the end of the session the phase III student must be able to clinically identify a plaque of psoriasis	08.04.2020
	B.At the end of the session the phase III student must be able to	
	enumerate differential diagnosis of psoriatic lesion	
	State and other diagnosts of poortage toolors	
	C.At the end of the session the phase III student must be able	
	tojustify the diagnosis of a psoriatic lesion and distinguish it from	
	other causes	
Y	A.At the end of the session the phase III student must be able to	08.04.2020
	list the three stages of the Auspitz sign and correctly	
	demonstrate the grattage test	

ī		
Y	A.At the end of the session the phase III student must be able to enumerate the indications for treatment of psoriasis	08.04.2020
	B.At the end of the session the phase III student must be able to	
	describe the various topical treatment options for psoriasis	
	C.At the end of the session the phase III student must be able to	
	describe the various systemic treatment options for psoriasis	
	D.At the end of the session the phase III student must be able to	
	describe the use of phototherapy for the treatment of psoriasis	
tencies:(02)	Number of procedures that require certificaion:(NIL)	
Y	A.At the end of the session the phase III student must be able to clinically identify a lesion of lichen planus and justify the diagnosis	11.04.2020
	B.At the end of the session the phase III student must be able to enumerate the differential diagnosis of lichen planus	
	C.At the end of the session the phase III student must be able to distinguish lichen planus from other caises	
Y	A.At the end of the session the phase III student must be able to enumerate the various treatment modalities for lichen planus	11.04.2020
	B.At the end of the session the phase III student must be able todescribe the various treatment modalities for lichen planus	
	Number of competencies :(03)	Number of pro
	A.At the end of the session the phase III student must be able to describe the etiology of scabies	15.04.2020
	B.At the end of the session the phase III student must be able to describe the life cycle of the scabies mite	
	C.At the end of the session the phase III student must be able to describe the pathogenesis of scabies	
Y	D.At the end of the session the phase III student must be able to describe the natural history of scabies	
	E.At the end of the session the phase III student must be able to describe the clinical features of scabies in adults	
	F.At the end of the session the phase III student must be able to describe the presentation of scabies in children	15.04.2020
	G.At the end of the session the phase III student must be able to describe the complications of scabies in children	15.04.2020

	A.At the end of the session the phase III student must be able to	18.04.2020
	clinically identify the lesions of scabies in children	
	David I file in the III of the II	
	B.At the end of the session the phase III student must be able to	
	clinically identify the lesions of scabies in adults	
	C.At the end of the session the phase III student must be able to	
	enumerate the differential diagnosis of scabies in children	
Y	D At the and of the session the phase III student must be able to	19.04.2020
1	D.At the end of the session the phase III student must be able to enumerate the differential diagnosis of scabies in adults	18.04.2020
	enumerate the differential diagnosis of scaples in addits	
	E.At the end of the session the phase III student must be able to	
	clinically diagnose scabies and clinically differentiate from other causes	
	in children	
	F.At the end of the session the phase III student must be able	
	todiagnose scabies and clinically differentiate the lesions of scabies	
	from other causes in adults	
	A. At the end of the session the phase III student must be able to	18.04.2020
	enumerate various treatment options for the treatment of scabies	10.01.2020
	1	
	B. At the end of the session the phase III student must be able to	
	describe the pharmacology of permethrin and ivermectin in scabies	
Υ	C. At the end of the session the phase III student must be able to	
	describe the correct mode of administration of various topical and oral	
	drugs used for the treatment of scabies	
	D. At the end of the session the phase III student must be able to	
	describe the adverse reactions to the pharmacotherapies for scabies	
		of procedures that
Υ	IA At the end of the ecceion the phace III student must be able. I	
•	A. At the end of the session the phase III student must be able	22.04.2020
	to describe the etiology of pediculosis	22.04.2020
	to describe the etiology of pediculosis	22.04.2020
·	to describe the etiology of pediculosis B. At the end of the session the phase III student must be able	22.04.2020
	to describe the etiology of pediculosis	22.04.2020
	to describe the etiology of pediculosis B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis	22.04.2020
	b. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able	22.04.2020
	to describe the etiology of pediculosis B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis	22.04.2020
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults	22.04.2020
	b. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able	22.04.2020
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults	22.04.2020
Y	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children	
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able	22.04.2020
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin	
	b. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis	
	b. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis B. At the end of the session the phase III student must be able	
	b. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis	
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in	
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in children	
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in children C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in	
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis C.At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children A. At the end of the session the phase III student must be able todescribe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in children C. At the end of the session the phase III student must be able	

	Number of competencies: (03)	Number of pro
	A. At the end of the session the phase III student must be able	25.04.2020
	to describe the etiology of dermatophytes	
	D. At the and of the ages in the release W. A. J. A. J. J.	
	B. At the end of the session the phase III student must be able	
	to describe the microbiology of dermatophytes	
	C. At the end of the session the phase III student must be able	
	to describe the pathogenesis of dermatophytes	
Υ	D. At the end of the session the phase III student must be able	
Y	to describe the clinical presentations of dermatophytes in children	
	E. At the end of the session the phase III student must be able	
	to describe the clinical presentations of dermatophytes in adults	
	F.At the end of the session the phase III student must be able	25.04.2020
	to describe the diagnostic features of dermatophytes in adults	
	G.At the end of the session the phase III student must be able	25.04.2020
	to describe the diagnostic features of dermatophytes in children	23.01.2020
Y	H.At the end of the session the phase III student must be able to	25.04.2020
1	identify Candida species in fungal scrapings and KOH mount	
	I. At the end of the session the phase III student must be able to	25.04.2020
	describe the pharmacology of systemic antifungal agents	
		25.04.2020
	Lattle and of the appoint the phase III student much health to	25.04.2020
	J.At the end of the session the phase III student must be able to describe the pharmacology of topical antifungal agents	25.04.2020
	describe the pharmacology of topical antifungal agents	
Υ	K. At the end of the session the phase III student must be able	25.04.2020
	to describe the mechanism of action of systemic antifungal	
	agents	
	L.At the end of the session the phase III student must be able to	25.04.2020
	describe the mechanism of action of topical antifungal agents	
	M. At the end of the session the phase III student must be able	25.04.2020
	to enumerate the side effects of antifungal therapy	
	Number of competencies (07)	Number of pro
Y	A.At the end of the session the phase III student must be able	29.04.2020
	to describe the etiology of common viral infections which include varicella zoster, herpes simples, viral warts and molluscum	
	contagiosum	
	B.At the end of the session the phase III student must be able	29.04.2020
	to describe the microbiology of common viral infections of the	
	skin	
	C. At the end of the session the phase III student must be able	29.04.2020
	to describe the pathogenesis of the common viral infections of	
	the skin	

D. At the end of the session the phase III student must be able to describe the clinical presentations of common viral infections of the skin in children E. At the end of the session the phase III student must be able to describe the clinical presentations of common viral infections of the skin in adults F. At the end of the session the phase III student must be able to describe the diagnostic features of common viral infections of the skin in children A. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes simplex B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labilation to clinically identify the skin lesions of herpes simplex C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella A. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella A. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varial warts C. At the end o	-		
to describe the clinical presentations of common viral infections of the skin in adults F. At the end of the session the phase III student must be able to describe the diagnostic features of common viral infections of the skin in children A. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes simplex B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labialis C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions of herpes zoster E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster Y H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to elinically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to elinically identify the skin lesions of viral warts C. At the end of the session the phase		to describe the clinical presentations of common viral infections	29.04.2020
F. At the end of the session the phase III student must be able to describe the diagnostic features of common viral infections of the skin in children A. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes simplex B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labialis C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to ijustify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to elimically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to elimically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to elimically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to elimically id		- I	29.04.2020
to describe the diagnostic features of common viral infections of the skin in children A. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes simplex B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labialis C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster Y H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella A. At the end of the session the phase III student must be able to clinically identify the skin lesions of variel warts B. At the end of the session the phase III student must be able to clinically identify the skin lesions of variel warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts D. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts D. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts to enumerate the differential diagnosis of viral warts to enumerate the differen		•	29.04.2020
to clinically identify the skin lesions of herpes simplex B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labialis C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum		to describe the diagnostic features of common viral infections of	29.04.2020
to clinically identify the skin lesions of herpes labialis C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum		·	29.04.2020
to enumerate the differential diagnosis of herpes simplex D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster Y H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able instify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum		- I	29.04.2020
D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts D. At the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able in the end of the session the phase III student must be able i	Y	•	29.04.2020
to justify the diagnosis of hepres simplex and distinguish lesions of herpes simplex from other skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum		to originate the americana diagnosis or herpos emplex	29.04.2020
to clinically identify the skin lesions of herpes zoster F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum		to justify the diagnosis of hepres simplex and distinguish lesions	29.04.2020
to clinically identify the skin lesions of primary varicella G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum		·	29.04.2020
to enumerate the differential diagnosis of herpes zoster H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum 29.04.2020		·	29.04.2020
I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions E. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum	Y	•	29.04.2020
justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warsts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum 29.04.2020		•	29.04.2020
A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warsts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum 29.04.2020		justify the diagnosis of herpes zoster and differentiate the skin	29.04.2020
to clinically identify the skin lesions of viral warts B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warsts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum			29.04.2020
B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts C. At the end of the session the phase III student must be able justify the diagnosis of viral warsts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum		-	29.04.2020
justify the diagnosis of viral warsts and be able to distinguish viral warts from other skin lesions D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum	Y		29.04.2020
to clinically identify the skin lesions of molluscum contagiosum E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum 29.04.2020		justify the diagnosis of viral warsts and be able to distinguish	29.04.2020
to enumerate the differential diagnosis of molluscum		• • • • • • • • • • • • • • • • • • •	29.04.2020
Y I		- I	29.04.2020
	Y		29.04.2020

	F.At the end of the session the phase III student must be able to justify the diagnosis of molluscum contagiosum and distinguish molluscum contagiosum from other skin lesions	29.04.2020
	A. At the end of the session the phase III student must be able to enumerate the indications of tzanck smear	29.04.2020
Y	B. At the end of the session the phase III student must be able to describe the procedure to perform a tzanck smear	29.04.2020
	C. At the end of the session the phase III student must be able to perform a tzanck smear	29.04.2020
Y	A.At the end of the session the phase III student must be able to enumerate the indications for pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies and	29.04.2020
	physical modalities for common viral illnesses of the skin	29.04.2020
	C. At the end of the session the phase III student must be able to describe the mode of administration of pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
	D. At the end of the session the phase III student must be able to describe the adverse reactions of pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
	Number of competencies: (07)	Number of pro
Y	A. At the end of the session the phase III student must be able to describe the epidemiology of leprosy	02.05.2020
	B. At the end of the session the phase III student must be able to describe the etiology of leprosy	
	C. At the end of the session the phase III student must be able to describe the microbiology of leprosy	
	D. At the end of the session the phase III student must be able to describe the clinical presentations of leprosy and classify the spectrum of leprosy	02.05.2020
	E. At the end of the session the phase III student must be able to describe the diagnostic features of leprosy	
	F. At the end of the session the phase III student must be able	
	to demonstrate the clinical features of leprosy	

Y	based on the clinical features	
	H.At the end of the session the phase III student must be able to demonstrate an appropriate neurological examination on a patient of leprosy	02.05.2020
Y	A.At the end of the session the phase III student must be able to enumerate the indications for performing a slit skin smear in patients with leprosy	02.05.2020
-	B. At the end of the session the phase III student must be able to enumerate the steps and observe the performance of a slit skin smear in patients with leprosy	02.05.2020
	A. At the end of the session the phase III student must be able to enumerate the types of lepra reaction	02.05.2020
	B. At the end of the session the phase III student must be able to describe the clinical features of of lepra reactions	
Y	C.At the end of the session the phase III student must be able to clinically identify the types of lepra reactions	
	D. At the end of the session the phase III student must be able to describe the supportive measures for the management of lepra reactions	
	E. At the end of the session the phase III student must be able to describe the pharmacotherapy of lepra reactions	
	A. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
Y	C.At the end of the session the phase III student must be able to describe the administration of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
	D. At the end of the session the phase III student must be able to describe the adverse reaction of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
Y	A. At the end of the session the phase III student must be able to describe the treatment of Leprosy based on the WHO guidelines	02.05.2020
Y	A.At the end of the session the phase III student must be able to enumerate the complications of leprosy	02.05.2020
	B. At the end of the session the phase III student must be able to describe the complications of leprosy	02.05.2020
	C. At the end of the session the phase III student must be able to describe the management of complications of leprosy	02.05.2020

	D. At the end of the session the phase III student must be able to describe the disabilities associated with leprosy	02.05.2020
	E. At the end of the session the phase III student must be able to understand the stigma associated with leprosy	02.05.2020
ases	Number of competencies: (11)	Number of proc
Y	A. At the end of the session the phase III student must be able	•
	to identify a clinical case of syphilis	06.05.2020
	B. At the end of the session the phase III student must be able to classify the stage of syphilis based on clinical presentation	06.05.2020
	C. At the end of the session the phase III student must be able to describe the clinical manifestations of syphilis	06.05.2020
	D. At the end of the session the phase III student must be able to identify spirochete in a dark ground microscopy	
Υ		06.05.2020
Y	E. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for syphilis	06.05.2020
	F. At the end of the session the phase III student must be able	
	to describe the pharmacology of pharmacotherapies for syphilis	06.05.2020
	G. At the end of the session the phase III student must be able	
	to describe the administration of pharmacotherapies for syphilis	06.05.2020
	H. At the end of the session the phase III student must be able	06.05.2020
Y	to describe the adverse reaction of pharmacotherapies for	06.05.2020
	A. At the end of the session the phase III student must be able to describe the prevention of congenital syphilis	06.05.2020
Y	A. At the end of the session the phase III student must be able to counsel in a non-judgemental and empathetic manner patients on prevention of sexually transmitted disease	
		06.05.2020
Y	A. At the end of the session the phase III student must be able to describe the etiology of chancroid	06.05.2020
	B. At the end of the session the phase III student must be able to describe the diagnostic features of chancroid	
		06.05.2020
	C. At the end of the session the phase III student must be able to describe the clinical features of chancroid	06.05.2020
	D. At the end of the session the phase III student must be able to describe the etiology of donovanosis	
		06.05.2020
	E. At the end of the session the phase III student must be able to describe the diagnostic features of donovanosis	06.05.2020
	F. At the end of the session the phase III student must be able to describe the clinical features of donovanosis	06.05.2020
	G. At the end of the session the phase III student must be able to describe the etiology of LGV	
		06.05.2020

H.At the end of the session the phase III student must be able to describe the diagnostic features of LGV I.At the end of the session the phase III student must be able to describe the clinical features of LGV Y. A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid C. to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the admin			
I.At the end of the session the phase III student must be able to describe the clinical features of LGV Y A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of J. GO. DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E. At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of th		· ·	
I.At the end of the session the phase III student must be able to describe the clinical features of LGV Y A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to enumerate the indications for use of drugs used for the management of chancroid C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the		to describe the diagnostic features of LGV	
Y A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE At the end of the session the phase III student must be able to difficentiate chancroid from other non-syphilitic sexually transmitted diseases E. At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid D. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of do			06.05.2020
Y A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the ma			
A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE. At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to enumerate the indications for use of drugs to the management of chancroid D. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the phase according to the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of		describe the clinical features of LGV	
be clinically identify the lesions of chancroid B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate chorovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid C. to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the phane maclogy of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the phase used for the manage			06.05.2020
B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the phase so the phase III student must be able to describe the phase so the phase III student must be able to describe the phase service of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for th	Υ	A. At the end of the session the phase III student must be able	
to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of LGV K. At the end of the sess		to clinically identify the lesions of chancroid	06.05.2020
to clinically identify the lesions of donovanosis C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of LGV K. At the end of the sess		B. At the end of the session the phase III student must be able	
C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid F. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of the session the phase III student must be able to enumerate the indications f			06.05.2020
to clinically identify the lesions of LGV DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid C. to describe the pharmacology of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of the phase III student must be able to describe the pharmacology of drugs used for the ma			
DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the		•	06.05.2020
to differentiate chancroid from other non-syphilitic sexually transmitted diseases E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanonsis G. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications			
E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases 7 A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able To to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J.		•	
E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis			06.05.2020
to differentiate donovanosis from other non-syphilitic sexually transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the pharmacolo			00.03.2020
transmitted diseases F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y. A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the adverse of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of dnovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of dnovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of describe the adverse effects of drugs used for the management of describe the adverse effects of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharma		· · · · · · · · · · · · · · · · · · ·	06.05.0000
to differentiate LGV from other non-syphilitic sexually transmitted diseases Y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis			06.05.2020
y A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the management of describe the pharmacology of drugs used for the		·	
A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis K. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of describe the pharmacology of drugs used for the		1	
to enumerate the indications for use of drugs for the management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis used for t			06.05.2020
management of chancroid B. At the end of the session the phase III student must be able C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the	Υ		
B. At the end of the session the phase III student must be able 06.05.2020 C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		to enumerate the indications for use of drugs for the	
C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		management of chancroid	06.05.2020
C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		B. At the end of the session the phase III student must be able	
C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		·	
C. to describe the pharmacology of drugs used for the management of chancroid D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			06.05.2020
D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		C. to describe the pharmacology of drugs used for the	
D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to describe the indications for use of drugs for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		management of chancion	06.05.2020
to describe the administration of drugs used for the management of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to enumerate the pharmacology of drugs used for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		D. At the end of the session the nhase III student must be able	00.03.2020
of chancroid E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		· ·	06.05.2020
to describe the adverse effects of drugs used for the management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			00.03.2020
management of chancroid F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis 06.05.2020 G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis 06.05.2020 H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis 06.05.2020 I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis 06.05.2020 J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		-	06.05.2020
to enumerate the indications for use of drugs for the management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		ÿ	06.05.2020
management of donovanosis G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		•	
G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis 06.05.2020 H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis 06.05.2020 I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis 06.05.2020 J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
to describe the pharmacology of drugs used for the management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		ů.	06.05.2020
management of donovanosis H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		•	
H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
to describe the administration of drugs used for the management of donovanosis 06.05.2020 I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis 06.05.2020 J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		management of donovanosis	06.05.2020
to describe the administration of drugs used for the management of donovanosis 06.05.2020 I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis 06.05.2020 J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		H.At the end of the session the phase III student must be able	
of donovanosis I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		· ·	
I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			06.05.2020
describe the adverse effects of drugs used for the management of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
of donovanosis J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			
J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			06.05.2020
enumerate the indications for use of drugs for the management of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the			00.00.2020
of LGV 06.05.2020 K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		•	
K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the		•	06.05.2020
to describe the pharmacology of drugs used for the			00.03.2020
· · · · · · · · · · · · · · · · · · ·		•	
management of LGV 06.05.2020			06.05.2020
		management of LGV	06.05.2020

•		
	L.At the end of the session the phase III student must be able to	
	describe the administration of drugs used for the management of	
	LGV	06.05.2020
	M. At the end of the session the phase III student must be able	
	to describe the adverse effects of drugs used for the	
	management of LGV	06.05.2020
Y	A. At the end of the session the phase III student must be able	
	to enumerate the ulcerative sexually transmitted diseases	
	·	06.05.2020
	B. At the end of the session the phase III student must be able	
	to describe the syndromic approach to ulcerative sexually	
	transmitted disease	06.05.2020
	C. At the end of the session the phase III student must be able	
	to describe the etiology of gonococcal urethritis	
	to describe the energy of genecodeal dreaming	06.05.2020
Y	D. At the end of the session the phase III student must be able	00.03.2020
'	· · · · · · · · · · · · · · · · · · ·	
	to describe the etiology of non-gonococcal urethritis	06.05.2020
		06.05.2020
	E. At the end of the session the phase III student must be able	06.05.2020
	to describe the diagnostic features of gonococcal urethritis	00.03.2020
		0.5.07.2020
		06.05.2020
	F. At the end of the session the phase III student must be able	
	to describe the diagnostic features of non-gonococcal urethritis	
		06.05.2020
	G. At the end of the session the phase III student must be able	
	to describe the clinical features of gonococcal urethritis	
		06.05.2020
	H.At the end of the session the phase III student must be able	
	to describe the clinical features of non-gonococcal urethritis	
		06.05.2020
	I.At the end of the session the phase III student must be able to	
	describe the management of gonococcal urethritis	
		06.05.2020
	J.At the end of the session the phase III student must be able to	00.02.2020
	describe the management of non-gonococcal urethritis	
	describe the management of non-gonococcar dreamins	06.05.2020
Y	A.At the end of the session the phase III student must be able	00.03.2020
'	to describe the etiology of vaginal discharge	
	to describe the ethology of vaginal discharge	06.05.2020
	D. At the and of the assign the relicion the relicion to the second seco	00.05.2020
	B. At the end of the session the phase III student must be able	
	to describe the various causes of vaginal discharge	06.05.2020
		06.05.2020
	C.At the end of the session the phase III student must be able	
	to describe the clinical features of the various causes of vaginal	
	discharge	06.05.2020
	D.At the end of the session the phase III student must be able	
	to describe the management of the pathological causes of	
	vaginal discharge	06.05.2020
	Number of competencies: (03)	Number of pro
Y	A.At the end of the session the phase III student must be able	09.05.2020
_	to describe the etiology of HIV	07.03.2020
	B.At the end of the session the phase III student must be able	09.05.2020
		07.03.2020
	to describe the pathogenesis of HIV	

Y	C.At the end of the session the phase III student must be able to describe the clinical features of the dermatologic manifestations of HIV D.At the end of the session the phase III student must be able to describe the complications of HIV	09.05.2020 09.05.2020
Y	D.At the end of the session the phase III student must be able	09.05.2020
Y	•	
Y	to describe the complications of this	09.05.2020
Y	E.At the end of the session the phase III student must be able to describe the opportunistic infections associated with HIV	09.05.2020
	A.At the end of the session the phase III student must be able to clinically identify the dermatological manifestations of HIV	09.05.2020
	B.At the end of the session the phase III student must be able to clinically distinguish the dermatological manifestations of HIV from other causes	09.05.2020
	C. At the end of the session the phase III student must be able to clinically identify the complications of HIV	09.05.2020
	D. At the end of the session the phase III student must be able to clinically identify the opportunistic infections associated with HIV	09.05.2020
	E. At the end of the session the phase III student must be able to distinguish the adverse reactions associated with management of HIV	09.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	C. At the end of the session the phase III student must be able to describe the administration of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	D. At the end of the session the phase III student must be able to describe the adverse effects of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	Number of competencies: (07)	Number of pr
Y	A. At the end of the session the phase III student must be able to describe the aetiopathogenesis of eczema	13.05.2020
Y	B. At the end of the session the phase III student must be able to clinically identify the cutaneous lesions of eczema C. At the end of the session the phase III student must be able to differentiate eczema from lichenification	13.05.2020
	D. At the end of the session the phase III student must be able to differentiate eczema from changes of aging	13.05.2020
V	A. At the end of the session the phase III student must be able to classify eczema	
Y	B. At the end of the session the phase III student must be able to grade eczema	13.05.2020
	A. At the end of the session the phase III student must be able to enumerate the indications of drugs used in the treatment of eczema	13.05.2020

-		
	B. At the end of the session the phase III student must be able	
	to describe the pharmacology of drugs used in the treatment of	
37	eczema	
Y	C. At the end of the session the phase III student must be able	
	to describe the topical and systemic administration of drugs used	
	in the treatment of eczema	
	D. At the end of the session the phase III student must be able	
	to describe the adverse reactions of drugs used in the treatment	
	of eczema	
		12.07.2020
	A. At the end of the session the phase III student must be able	13.05.2020
	to define erythroderma	
	B. At the end of the session the phase III student must be able	13.05.2020
	to enumerate the causes of erythroderma	
Y		
	C. At the end of the session the phase III student must be able	13.05.2020
	to identify the causes of erythroderma	
	D. At the end of the session the phase III student must be able	13.05.2020
	to describe the topical and systemic treatment of the various	
	types of erythroderma	
	A. At the end of the session the phase III student must be able	13.05.2020
	to clinically identify exfoliative dermatitis	13.03.2020
	B. At the end of the session the phase III student must be able	13.05.2020
	to enumerate the differential diagnosis of exfoliative dermatitis	13.03.2020
Y	to enumerate the differential diagnosis of extoliative definations	
1		
	C. At the and of the assertion the phase III student must be able	12.07.2020
	C. At the end of the session the phase III student must be able	13.05.2020
	to distinguish exfoliative dermatitis from other skin lesions	
V	A At the and of the accessor the whole III student must be able	12.05.2020
Y	A. At the end of the session the phase III student must be able	13.05.2020
	to identify the lesions of fixed drug eruptions	
	B. At the end of the session the phase III student must be able	
	to enumerate the differential diagnosis of fixed drug eruptions	
	C. At the end of the session the phase III student must be able	
	to distinguish fixed drug eruptions from other skin lesions	
	D. At the end of the session the phase III student must be able	
	to identify the skin lesions of Steven Johnson syndrome	
	E. At the end of the session the phase III student must be able	
	to enumerate the differential diagnosis of Steven Johnson	
	syndrome	
	F. At the end of the session the phase III student must be able	
	to distinguish Steven Johnson syndrome from other skin lesions	
	,	
3) Nu	imber of procedures that require certificaion:(NIL)	
Y	A. At the end of the session the phase III student must be able	16.05.2020
•	to define a vesicle	10.03.2020
	as as a vocation	
	B. At the end of the session the phase III student must be able	16.05.2020
	to define a bulla	10.03.2020
	lo deline a bulla	

	C. At the end of the session the phase III student must be able to distinguish a bulla from vesicle	16.05.2020
Y	A. At the end of the session the phase III student must be able to demonstrate a tranck smear	16.05.2020
	B. At the end of the session the phase III student must be able	
	to demonstrate nikolsky sign C. At the end of the session the phase III student must be able	
	to demonstrate bulla spread sign	
Y	D. At the end of the session the phase III student must be able	16.05.2020
	to calculate the body surface area of involvement of	
	vesiculobullous lesions	
5)	Number of procedures that require certificaion:(NIL)	
Υ	A. At the end of the session the phase III student must be able	
	to describe the etiology of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able	
	to describe the pathogenesis of urticaria	20.05.2020
	C. At the end of the session the phase III student must be able	
	to describe the clinical features of urticaria	20.05.2020
	D. At the end of the session the phase III student must be able	20.05.2020
	D. At the end of the session the phase III student must be able to describe the precipitating factors for urticaria	
	to describe the precipitating factors for unicana	20.05.2020
	E. At the end of the session the phase III student must be able	
	to describe the classification of urticaria	20.05.2020
	F.At the end of the session the phase III student must be able	20.03.2020
	to describe the etiology of angioedema	
	• •	20.05.2020
	G. At the end of the session the phase III student must be able	
	to describe the pathogenesis of angioedema	20.05.2020
	H.At the end of the session the phase III student must be able	
	to describe the clinical features of angioedema	20.07.2020
	At the end of the end of the place Western the place	20.05.2020
	I. At the end of the session the phase III student must be able to describe the precipitating factors of angioedema	
	describe the precipitating factors of angioedema	20.05.2020
	J. At the end of the session the phase III student must be able	
	to describe the classification of angioedema	20.05.2020
	A. At the end of the session the phase III student must be able	20.05.2020
	to clinically identify the cutaneous lesions of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able	20.03.2020
Y	to enumerate the differential diagnosis of urticaria	
	to onemorate the uniformal diagnosis of artisand	20.05.2020
	C. At the end of the session the phase III student must be able	
	to distinguish urticaria from other skin lesions	20.05.2020
V	A. At the end of the session the phase III student must be able	
Y	to demonstrate dermographism	20.05.2020
	A. At the end of the session the phase III student must be able	
	to clinically identify the lesions of angioedema	20.05.2020
		20.05.2020
	B. At the end of the session the phase III student must be able	
Y	to enumerate the differential diagnosis of angioedema	
		20.05.2020

İ	A	
	C. At the end of the session the phase III student must be able	
	to distinguish angioedema from other skin lesions	
		20.05.2020
	A. At the end of the session the phase III student must be able	
	to enumerate the indications of drugs used in the management	
	of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able	
	to describe the pharmacology of drugs used in the management	
	of urticaria	20.05.2020
	C. At the end of the session the phase III student must be able	20.03.2020
	•	
	to describe the administration of drugs used in the management	20.05.2020
	of urticaria	20.05.2020
	D. At the end of the session the phase III student must be able	
Y	to describe the adverse reactions of drugs used in the	
	management of urticaria	20.05.2020
	E. At the end of the session the phase III student must be able	
	to enumerate the indications of drugs used in the management	
	of angioedema	20.05.2020
	F. At the end of the session the phase III student must be able	
	to describe the pharmacology of drugs used in the management	
	of angioedema	20.05.2020
		20.05.2020
	G. At the end of the session the phase III student must be able	
	to describe the administration of drugs used in the management	
	of angioedema	20.05.2020
) Num	ber of procedures that require certificaion:(NIL)	
Y	A. At the end of the session the phase III student must be able	
	to identify the cutaneous lesions of folliculitis	23.05.2020
	B. At the end of the session the phase III student must be able	
	to identify the cutaneous lesions of impetigo	23.05.2020
	C. At the end of the session the phase III student must be able	23.03.2020
	•	22.05.2020
	to identify the cutaneous lesions of carbuncle	23.05.2020
	D. At the end of the session the phase III student must be able	
	to distinguish the cutaneous lesions of folliculitis from other skin	
	lesions	23.05.2020
	E.At the end of the session the phase III student must be able	22 07 2020
	to distinguish the cutaneous lesions of impetigo from other skin	23.05.2020
	lesions	
		23.05.2020
	F.At the end of the session the phase III student must be able	
	to distinguish the cutaneous lesions of carbuncle from other skin	
	lesions	23.05.2020
Y	A. At the end of the session the phase III student must be able	
1	to identify staphylococcus on a gram stain	23.05.2020
Y	A.At the end of the session the phase III student must be able	
1	to list the topical drugs used in treatment of pyoderma and	
	describe the indications of the topical drugs in pyoderma	
	juesonibe the indications of the topical drugs in pyodeinia	22.05.2020
		23.05.2020
	B.At the end of the session the phase III student must be able	
	to describe the pharmacology of topical drugs used in treatment	
	of pyoderma	23.05.2020
	C. At the end of the session the phase III student must be able	
	to describe theadministration of topical drugs used in treatment	
	of pyoderma	23.05.2020
Ī	L1	25.05.2020

1		Τ
	D. At the end of the session the phase III student must be able	
	to describe the adverse reactions of topical drugs used in	
	treatment of pyoderma	23.05.2020
	E.At the end of the session the phase III student must be able	
	to enumerate the indications of systemic drugs used in	
	treatment of pyoderma	23.05.2020
	F.At the end of the session the phase III student must be able	
	to describe the pharmacology of systemic drugs used in	
	treatment of pyoderma	23.05.2020
	G. At the end of the session the phase III student must be able	
	to describe the administration of systemic drugs used in	
	treatment of pyoderma	23.05.2020
	H. At the end of the session the phase III student must be able	
	to describe the adverse reactions of systemic drugs used in	
	treatment of pyoderma	23.05.2020
Y	A. At the end of the session the phase III student must be able to	23.03.2020
1	enumerate the indications for surgical referral.	22.05.2020
		23.05.2020
2)	Number of procedures that require certification:(NIL)	
Y	A. At the end of the session the phase III student must be able	
1	to identify the skin lesions of SLE	27.05.2020
1	B. At the end of the session the phase III student must be able	
	to enumerate the differential diagnosis of the cutaneous	
	manifestations of SLE	27.05.2020
	C. At the end of the session the phase III student must be able	
	to distinguish the skin lesions of SLE from other skin lesions	
	10 4.0 94.0 4 00.0	27.05.2020
Y	A. At the end of the session the phase III student must be able	27.03.2020
1	to describe the three phases and identify Raynaud's	
	phenomenon	27.05.2020
	ı .	27.03.2020
	B. At the end of the session the phase III student must be able	27.05.2020
	to enumerate the differential diagnosis of Raynaud's	
	phenomenon	27.05.2020
	C. At the end of the session the phase III student must be able	
	to distinguish the various causes of Raynaud's phenomenon	
		27.05.2020
4)	Number of procedures that require certificaion:(NIL)	
Y	A. At the end of the session the phase III student must be able	
	to enumerate the cutaneous findings in vitamin A deficiency	
		30.05.2020
	B. At the end of the session the phase III student must be able	
	to identify the cutaneous findings in vitamin A deficiency	
	To racinary and carameters among an internal field	30.05.2020
Y	A. At the end of the session the phase III student must be able	30.03.2020
'		
	to enumerate the various skin changes in Vitamin B complex	20.05.2020
	deficiency	30.05.2020
1	B. At the end of the session the phase III student must be able	
	to describe the various skin changes in Vitamin B complex	20.07.7
	deficiency	30.05.2020
Y	A. At the end of the session the phase III student must be able	
	to enumerate the various changes in Vitamin C deficiency	
		30.05.2020
	B. At the end of the session the phase III student must be able	
	to describe the various changes in Vitamin C deficiency	
1	Í	30.05.2020
		30.03.2020

Y	A. At the end of the session the phase III student must be able to enumerate the various skin changes in Zinc deficiency	
		30.05.2020
	B. At the end of the session the phase III student must be able to describe the various skin changes in Zinc deficiency	
	·	30.05.2020
2) N	lumber of procedures that require certification:(NIL)	
Y	A. At the end of the session the phase III student must be able to enumerate the cutaneous features of Type 2 diabetes	
		03.06.2020
Y	B. At the end of the session the phase III student must be able to enumerate the cutaneous features of hypo/hyper-thyroidism	
		03.06.2020
amunication		

		03.06.2020
-	, Column F: DOAP session – Demonstrate, Observe, Assess, P dependently for certification/ graduation	erform.
	Integration	
Core (Y/N)		Suggested Teaching Learning method
	Human Anatomy	!
Y	A.At the end of the session the phase III student must be able to describe the structure of skin	Lecture, DOAP session
	B. At the end of the session the phase III student must be able to describe the structure of skin appendages	Lecture, DOAP session
	C. At the end of the session the phase III student must be able to describe the functions of skin	Lecture, DOAP session
	D. At the end of the session the phase III student must be able to describe the functions of the skin appendages	Lecture, DOAP session
Y	A. At the end of the session the phase III student must be able to describe the modifications of deep fascia	Lecture, DOAP session
	B. At the end of the session the phase III student must be able to describe the functions of deep fascia	Lecture, DOAP session
N	A. At the end of the session the phase III student must be able to explain the principles of skin incisions	Lecture
	Pathology	•
Y	A. At the end of the session the phase III student must be able to describe the risk factors of squamous cell carcinoma of the skin	Lecture, Small group discussion
	B. At the end of the session the phase III student must be able to describe the pathogenesis of squamous cell carcinoma of the	Lecture, Small group discussion
	skin	Lecture, Small group discussion

ı		
		Lecture, Small
	C. At the end of the session the phase III student must be able	group discussion
	to describe the pathology of squamous cell carcinoma of the skin	
	D. At the end of the session the phase III student must be able	Lecture, Small
	to describe the natural history of squamous cell carcinoma of the skin	group discussion
Y	A. At the end of the session the phase III student must be able	Lecture, Small
	to describe the risk factors of basal cell carcinoma of the skin	group discussion
	B. At the end of the session the phase III student must be able	Lecture, Small
	to describe the pathogenesis of basal cell carcinoma of the skin	group discussion
	C. At the end of the session the phase III student must be able to	Lecture, Small
	describe the pathology of basal cell carcinoma of the skin	group discussion
	D. At the end of the session the phase III student must be able	Lecture, Small
	to describe the natural history of basal cell carcinoma of the skin	group discussion
	E. At the end of the session the phase III student must be able to	Lecture, Small
	describe the pathology of basal cell carcinoma of the skin	group discussion
	F. At the end of the session the phase III student must be able	Lecture, Small
	to describe the natural history of basal cell carcinoma of the skin	group discussion
N	A. At the end of the session the phase III student must be able	Lecture, Small
	to describe the clinical distinguishing features between a nevus and melanoma	group discussion
	B. At the end of the session the phase III student must be able	Lecture, Small
	to describe the etiology of melanoma	group discussion
	C. At the end of the session the phase III student must be able	Lecture, Small
	to describe the pathogenesis of melanoma	group discussion
	D. At the end of the session the phase III student must be able	Lecture, Small
	to describe the risk factors of melanoma	group discussion
	E. At the end of the session the phase III student must be able	Lecture, Small
	to describe the various morphological presentations of melanoma	group discussion
	F. At the end of the session the phase III student must be able	Lecture, Small
	to describe the clinical features of melanoma	group discussion
	G. At the end of the session the phase III student must be able	Lecture, Small
	to describe the metastases of melanoma	group discussion
N	A. At the end of the session the phase III student must be able	DOAP session
	to enumerate the common skin tumors	
	B. At the end of the session the phase III student must be able	DOAP session
	to identify the common skin tumors	
	C. At the end of the session the phase III student must be able	DOAP session
İ	to distinguish the common skin tumors	
	6	

	D. At the and of the assession the phage III student must be able	DOAP session
	D. At the end of the session the phase III student must be able to describe the common skin tumors	DOAP session
V	Microbiology A. At the end of the session the phase III student must be able	Lecture
Y		Lecture
	to describe the etio-pathogenesis of Skin and soft tissue	
	infections B. At the end of the session the phase III student must be able	Lecture
	to describe the clinical course of Skin and soft tissue infections	Lecture
	to describe the chinical course of 5km and soft tissue infections	
	C. At the end of the session the phase III student must be able	Lecture
	to describe the laboratory diagnosis of Skin and soft tissue	
	infections	
Y	A. At the end of the session the phase III student must be able	Lecture, Small
	to describe the etio-pathogenesis of sexually transmitted	group discussion
	infections	
	B. At the end of the session the phase III student must be able	Lecture, Small
	to describe the laboratory diagnosis of sexually transmitted	group discussion
	infections	
	C. At the end of the session the phase III student must be able	Lecture, Small
	to describe the preventive measures of sexually transmitted	group discussion
	infections	
	Pharmacology	
Y	A. At the end of the session the phase III student must be able	Lecture
	to describe the mechanism of action of antileprotic drugs	
	B. At the end of the session the phase III student must be able	Lecture
	to describe the types of antileprotic drugs	
		T a atrana
	C. At the end of the session the phase III student must be able	Lecture
	to describe the doses of antileprotic drugs	
	D. At the end of the session the phase III student must be able	Lecture
	to describe the side effects of antileprotic drugs	
	E.At the end of the session the phase III student must be able	Lecture
	to describe the indications of antileprotic drugs	
		Lastura
	F. At the end of the session the phase III student must be able	Lecture
	to describe the contraindications of antileprotic drugs	
Y	G.At the end of the session the phase III student must be able	Lecture
	to describe the common drugs used in skin disorders	
	Pediatrics	
	A. At the end of the session the phase III student must be able	Bedside clinics,
	to identify atopic dermatitis and justify the diagnosis	Skill Lab
	B. At the end of the session the phase III student must be able	Bedside clinics
	to manage a case of atopic dermatitis	
	6 r r	

Time	Suggested Teaching Learning methods	Suggested Assessment methods	Number required to certify P	Vertical integration	Horizontal Integration
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
equire certificaion:(NIL)					
08.30 to 9.30	Bedside clinic	Skill assessment			
	discussion				
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion and demonstration	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment/ Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			

08.30 to 9.30	Lecture, Small	Written/ Viva
08.30 to 9.30		
	group discussion	voce
		10000
	Lecture, Small	Written/ Viva
	group discussion	voce
	Lecture, Small	Written/ Viva
	group discussion	voce
	9	
	Lastina Ossall	Michigan IVI an
	Lecture, Small	Written/ Viva
	group discussion	voce
08.30 to 9.30	Bedside clinic	Skill assessment
08.30 to 9.30	Deuside Cillic	Skill assessifierit
	Lecture, Small	Written/ Viva
	group discussion	voce
	3. 2 S. P. G.	
	Bedside clinic	Skill assessment
08.30 to 9.30	Lecture, Small	Written/ Viva
	group discussion	voce
	Ĭ .	
	Lecture, Small	Written/ Viva
	group discussion	voce
	group disoussion	
ocedures that require c	ertificaion:(NIL)	
08.30 to 9.30	Lecture, Small	Written/ Viva
	group discussion	voce
	Ĭ .	
	Lecture, Small	Written/ Viva
	group discussion	voce
	group disoussion	
	Locture Cree!	Writton/ \/ivo
	Lecture, Small	Written/ Viva
	group discussion	voce
		100 :00 (20)
	Lecture, Small	Written/ Viva
	group discussion	voce
	Lecture, Small	Written/ Viva
	group discussion	voce
08.30 to 9.30	Lecture, Small	Written/ Viva
	group discussion	voce
08.30 to 9.30	Lecture, Small	Written/ Viva
	group discussion	voce
00.20 / 0.20	4	
08.30 to 9.30		
	i e	

08.30 to 9.30	Lecture, Small	Written/ Viva		
00.30 to 7.30	group discussion	voce		
	group discussion	VOCC		
	Bedside clinic	Skill assessment		
	Beaside Clinic	Skill assessment		
	D 1 1 1 1 1	01.111		
	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	1			
	Bedside clinic	Skill assessment		
	Dodoido omno	OKIII GOOGGOTTIOTIC		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
		10.0		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
require certificaion:(NIL)				
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	'			
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	3 a.coaoo.o.i			
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group discussion	1,000		
08.30 to 9.30	Bedside clinic	Skill assessment		
06.30 to 9.30	Deuside Cililic	JKIII assessment		
	Lastona C. "	VA / = 11 / \ / 2		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	-			
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Bedside clinic	Skill assessment		
	1	I		

08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce	ocedures that require	certificaion:(NIL)			
group discussion voce Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small group discussion Voce 08.30 to 9.30 Lecture, Small Written/ Viva Viva Viva Viva Viva Viva Viva Viva			Written/ Viva		
Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce Cedures that require certification: (NIL) Lecture, Small group discussion voce Lecture, Small group discussion voce Written/ Viva voce Written/ Viva voce Written/ Viva voce Lecture, Small group discussion voce Written/ Viva voce Lecture, Small group discussion voce Written/ Viva voce	00.30 to 7.30				
group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce		group discussion	1000		
group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion voce Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce Uritten/ Viva voce Written/ Viva voce		Locture Small	\\/ritton/\/ivo	1	
Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Description of the properties of the pro					
Group discussion Voce Lecture, Small group discussion Written/ Viva voce		group discussion	voce		
Group discussion Voce Lecture, Small group discussion Written/ Viva voce		0 "	NA 144 () /)		
Lecture, Small group discussion Description of the control of the					
group discussion voce Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 108.30 to 9.30 Lecture, Small group discussion voce		group discussion	voce		
group discussion voce Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 108.30 to 9.30 Lecture, Small group discussion voce					
Lecture, Small group discussion voce 08.30 to 9.30					
group discussion voce 08.30 to 9.30 Lecture, Small group discussion Written/ Viva voce		group discussion	voce		
group discussion voce 08.30 to 9.30 Lecture, Small group discussion Written/ Viva voce					
08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 DOAP session 08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 Lecture, Small Written/ Viva voce Lecture, Small group discussion Written/ Viva voce Lecture, Small group discussion Written/ Viva voce Lecture, Small group discussion Written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce		Lecture, Small	Written/ Viva		
group discussion voce 08.30 to 9.30		group discussion	voce		
group discussion voce 08.30 to 9.30					
group discussion voce 08.30 to 9.30	08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 DOAP session 08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 Lecture, Small Written/ Viva			voce		
group discussion voce 08.30 to 9.30 DOAP session Skill assessment		ا ا			
group discussion voce 08.30 to 9.30 DOAP session Skill assessment	08.30 to 9.30	Lecture, Small	Written/ Viva	1	
08.30 to 9.30 DOAP session Skill assessment 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce					
08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce Cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva voce		3 - 1, 3 - 2 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -			
08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce Cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva voce	08 30 to 9 30	DOAP session	Skill assessment		
group discussion voce 08.30 to 9.30	00.30 to 7.30	DO/ (1 30331011	Okiii assessinent		
group discussion voce 08.30 to 9.30					
08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva voce	08.30 to 9.30		Written/ Viva		
group discussion voce 08.30 to 9.30		group discussion	voce		
group discussion voce 08.30 to 9.30	08 30 to 0 30	Lactura Small	Writton/ Viva	1	
08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva voce	06.30 10 9.30				
group discussion voce 08.30 to 9.30		group discussion	VOCE		
group discussion voce 08.30 to 9.30	09 20 40 0 20	Looturo Cmall	Mritton/Mixo	ł	
08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 Lecture, Small group discussion 08.30 to 9.30 Lecture, Small group discussion Written/ Viva voce 08.30 to 9.30 Lecture, Small group discussion Written/ Viva voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion Written/ Viva voce Lecture, Small group discussion Written/ Viva voce Lecture, Small group discussion Written/ Viva voce Lecture, Small Written/ Viva voce	08.30 to 9.30				
group discussion voce 08.30 to 9.30		group discussion	voce		
group discussion voce 08.30 to 9.30	00.20 . 0.20		NA 144 () ()		
08.30 to 9.30 Lecture, Small group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce Cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva	08.30 to 9.30				
group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva		group discussion	voce		
group discussion voce 08.30 to 9.30 Lecture, Small group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small written/ Viva					
08.30 to 9.30 Lecture, Small group discussion cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion Voce Lecture, Small group discussion Lecture, Small group discussion Lecture, Small written/ Viva yoce Lecture, Small Written/ Viva Lecture, Small Written/ Viva	08.30 to 9.30				
group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva		group discussion	voce		
group discussion voce cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion voce Lecture, Small group discussion voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva					
cedures that require certification: (NIL) 08.30 to 9.30 Lecture, Small group discussion Lecture, Small group discussion Voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva	08.30 to 9.30		Written/ Viva		
08.30 to 9.30 Lecture, Small written/ Viva voce Lecture, Small Written/ Viva group discussion voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva		group discussion	voce		
08.30 to 9.30 Lecture, Small written/ Viva voce Lecture, Small written/ Viva group discussion voce Lecture, Small written/ Viva voce Lecture, Small Written/ Viva					
08.30 to 9.30 Lecture, Small written/ Viva voce Lecture, Small Written/ Viva group discussion voce Lecture, Small Written/ Viva voce Lecture, Small Written/ Viva	cedures that require of	certification: (NIL)			
group discussion voce Lecture, Small Written/ Viva group discussion voce Lecture, Small Written/ Viva			Written/ Viva		
Lecture, Small Written/ Viva group discussion voce Lecture, Small Written/ Viva					
group discussion voce Lecture, Small Written/ Viva			1		
group discussion voce Lecture, Small Written/ Viva					
group discussion voce Lecture, Small Written/ Viva		Lecture Small	Written/ Viva	i	
Lecture, Small Written/ Viva					
		group discussion	VOCE		
		Lastina Oiriall	Muittan / Missa		
group discussion voce					
		group discussion	voce		
				J	

	Lastina Casall	\\\/ \\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \			I
	Lecture, Small	Written/ Viva	1		
	group discussion	voce	1		
			1		
	Lecture, Small	Written/ Viva	1		
	aroup discussion	voce	·		
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce	1		
	group dioddoolori	1000	1		
00.00	1 , 0 "	10/1:44 / 10/1:			
08.30 to 9.30	Lecture, Small	Written/ Viva	1		
	group discussion	voce	1		
			1		
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce	1		
	• .				
08.30 to 9.30	DOAP session	Skill assessment	1		
			1		
08.30 to 9.30	DOAP session	Skill assessment			
08.30 to 9.30	Lecture, Small	Skill assessment/			
00.26 0.20	group discussion	Written/ Viva			
08.30 to 9.30		voce			
			i		
			1		
08.30 to 9.30	DOAP session	Skill assessment			
00.30 to 7.30	DO/11 30331011	Okiii doocoomont	1		
			1		
			r		
	DOAP session	Skill assessment	1		
			1		
			1		
	DOAP session	Skill assessment	1		
	DOAF SESSION	Okili assessifietit	1		
			1		
			1		
	Lecture, Small	Written/ Viva	1		
	group discussion	voce	1		
	3 - 1		1		
	Lastina Casall	Muitton/Misso	1		
	Lecture, Small	Written/ Viva	i		
	group discussion	voce	i		
		ļ			
	DOAP session	Skill assessment			
08.30 to 9.30					
			1		
	DOAP session	Skill assessment	i		
	DOVE 96991011	Oniii assessiiielil	i		
			1		
			i		
	DOAP session	Skill assessment	i		
			i		
			1		
00 20 +- 0 20	Locture Cree!	\\/ritto=/\/:		 	
08.30 to 9.30	Lecture, Small	Written/ Viva	i		
	group discussion	voce	i		
			i		
	DOAP session	Skill assessment	i		
			i		
	DOAP session	Skill assessment	i		
					ži

	Lastina C "	NA/-211 / N.P.	1	ı
	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	DOAP session	Skill assessment		
	20711 00001011	Ontin acceptance		
	Locture Small	Written/ Viva		
	Lecture, Small			
	group discussion	voce		
		124		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	DOAP session	skill assesment		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group discussion	VOCC		
			1	l
cedures that require		120 120	1	
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	g. 5 ap aloodololl			
08.30 to 9.30	Lecture, Small	Written/ Viva	 	
00.30 10 7.30	group discussion			
	group discussion	voce		
00.20 + 0.20	Lastura Cossell	Muitton / Minis		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Bedside clinic/		
		Skill assessment		
08.30 to 9.30	Bedside clinic	Bedside clinic/	 	l
	1	Skill assessment	1	I

00.20 - 0.20	Dadaida - Uni-	Dedeide -P-1-/	1	
08.30 to 9.30	Bedside clinic	Bedside clinic/		
		Skill assessment		
08.30 to 9.30	Bedside clinic	Bedside clinic/		
		Skill assessment		
08.30 to 9.30	Bedside clinic,	Written/ Viva		
08.30 to 9.30	DOAP session			
	DOAP SESSION	voce		
	Bedside clinic,	Skill assessment		
	DOAP session			
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.20 to 7.20	group discussion	voce		
	group disoussion	1,000		
	Lastina Ossall	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Bedside clinic	Bedside clinic		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.30 to 7.30	group discussion	voce		
	group discussion	VOCE		
08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 to 7.30		voce		
	group discussion	VOCE		
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.50 to 7.50	group discussion	voce		
	group discussion	1		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 10 9.30				
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group aloodoololl	1.300		
	Lasti O "	M/=:0 = 12.0		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group discussion	1		
1		ļ	I	I

	Lastina Creall	Muitton/Mino	1	1	ı
	Lecture, Small	Written/ Viva			
	group discussion	voce			
	Lootura Cmall	Written/ Viva			
	Lecture, Small				
	group discussion	voce			
edures that require o	ertification:(NIL)	<u>I</u>			
08.30 to 9.30	Bedside clinic	Skill assessment			
00.50 to 7.50	Bodordo om no	Citim dococomonic			
08.30 to 9.30	Bedside clinic	Skill assessment			
00.00 10 7.00					
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	DOAP session	Skill assessment			1
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
00 20 4- 0 20	group discussion	voce Written/ Viva			
08.30 to 9.30	Lecture, Small				
	group discussion	voce			
08.30 to 9.30	DOAP session	Skill assessment			
		100			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
		100			ļ
00.20		Written/ Viva		I	
08.30 to 9.30	Lecture, Small				
08.30 to 9.30	Lecture, Small group discussion	voce			
	group discussion	voce			
08.30 to 9.30 08.30 to 9.30					

		I		1
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	'			
08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 to 9.30				
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside Cillic	Skill assessifierit		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
00.50 to 7.50	Dodolao oliilio	Okiii addodddiiidiik		
08.30 to 9.30	Bedside clinic	Skill assessment		
00.20 . 0.20		01.31		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.50 to 7.50				
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	g. cap alecaesis.			
	 	101 101 111		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.50 to 7.50				
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	g. cap alecaesis.			
00.20 . 0.20		VAL 144 / V.C.		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	1,40.00		
	group discussion	voce		
	group discussion	voce		
08 30 to 9 30				
08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 to 9.30				
	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30 08.30 to 9.30	Lecture, Small	Written/ Viva		
	Lecture, Small group discussion Lecture, Small	Written/ Viva voce Written/ Viva		
	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce		
	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small	Written/ Viva voce Written/ Viva voce Written/ Viva		
08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small	Written/ Viva voce Written/ Viva voce Written/ Viva		
08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small	Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva		
08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce Written/ Viva voce		
08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small	Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva		
08.30 to 9.30 08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce		
08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva		
08.30 to 9.30 08.30 to 9.30 08.30 to 9.30	Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion Lecture, Small group discussion	Written/ Viva voce Written/ Viva voce Written/ Viva voce Written/ Viva voce		

	•		_		•
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva	1		
	group discussion	voce			
	group and and a				
08.30 to 9.30	Lecture, Small	Written/ Viva			
00.50 to 7.50	group discussion	voce			
	group discussion	Vocc			
00.20 / 0.20	Lastina Creal	Muitten / Mine			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
	-				
08.30 to 9.30	Lecture, Small	Written/ Viva			
	aroup discussion	voce	<u> </u>	<u> </u>	
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
00.30 to 7.30	group discussion	voce			
	group discussion	1,000			
08.30 to 9.30	Lecture, Small	Written/ Viva			
08.30 10 9.30					
	group discussion	voce			
		100			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
	3.5% 4.004001011				
08.30 to 9.30	Lecture, Small	Written/ Viva	┥		
00.30 10 7.30	group discussion	voce			
	Group discussion	VOCE			
00 20 4- 0 20	Looturo Cree!	\//ritto=/\/:	4		
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
			4		
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
edures that require ce	rtificaion:(NIL)		· · · · · · · · · · · · · · · · · · ·		
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
	Lecture, Small	Written/ Viva	1		
	group discussion	voce			
	group discussion	1,000			

				T
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
08.30 to 9.30	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	beuside cirric	Skiii assessitietit		
	Bedside clinic	Skill assessment		
	Deaside cirrio	Okiii addeddinent		
	5	0		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Deaside office	Okiii addeddinent		
08.30 to 9.30	Bedside clinic	Skill assessment		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group dioodoolon	1		
	Lastina Casall	\\/ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
ocedures that require	certificaion:(NIL)			
	Lecture, Small	Written/ Viva		
	group discussion	voce		
	group dioddoolori	1000		
	1			
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Deuside Cililic	Okiii assessinierit		
08.30 to 9.30	Locturo Cmall	Written/ Viva		
08.30 to 9.30	Lecture, Small			
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
00.20 10 7.20	group discussion	voce		
	19.04P 4.004001011	-555		
1			l l	

1		1	1	•	•
	Lecture, Small	Written/ Viva			
	group discussion	voce			
	Lecture, Small	Written/ Viva			
	group discussion	voce			
	Lecture, Small	Written/ Viva			
	group discussion	voce			
	g. 5 up u. 5 u 5 u 5 u 5 u 5 u 5 u 5 u 5 u 5 u				
08.30 to 9.30	Lecture, Small	Written/ Viva			
00.30 to 7.30	group discussion	voce			
	group discussion	VOCE			
08.30 to 9.30	Lecture, Small	Written/ Viva			
08.30 to 9.30					
	group discussion	voce			
08.30 to 9.30	Bedside clinic	Written/ Skill			
		assessment			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small	Skill assessment,			
	group discussion,	Written/ Viva			
	Bedside clinic	voce			
	Doddido dillilo	1000			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 10 9.30	beaside cillic	Skill assessment			
	5	0			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small	Written/ Viva			
	aroup discussion	voce. Skill			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Lecture, Small	Skill assessment,			
	group discussion	Written/ Viva			
	9.555 0.55000001	voce,			
	Bedside clinic	Skill assessment			
	Deusiue Cilliic	JAIII assessinelli			
		1			
	- 1.	T			
08.30 to 9.30	Lecture, Small	Written/ Viva			
	group discussion	voce			
	Lecture, Small	Written/ Viva			
	group discussion	voce			
Ī		I	Į.	I	

I	Desired P. C.	Touris	ı	I
	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
	'			
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
00 20 40 0 20	Bedside clinic	Skill assassment		
08.30 to 9.30	Deuside cilnic	Skill assessment		
	Lecture, Small	Skill assessment.		
	group discussion	Written/ Viva		
	3 - 1 - 1 - 1 - 1 - 1	voce		
•	-	•	•	•

	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
00.20 0.20)		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
	De de de alla la	Obill and a second		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Bedside clinic	Skill assessment		
	Beaside Cilriic	Skiii assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
	9 ap - a			
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
-	-		-	-

00.20 + 0.20	II a atuma. Cas all	\\\/ \\\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	1	
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce		
	group discussion	V000		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	Lecture, Small	Written/ Viva		
	group discussion	voce		
08.30 to 9.30	DOAP session	Written/ Viva		
08.30 to 9.30	DOAF Session	voce		
08.30 to 9.30	Bedside clinic	Skill assessment		
	Lecture, small	Written/ Viva		
	group discussion	voce		
	De del de eller	OL:		
	Bedside clinic	Skill assessment		
08.30 to 9.30	Bedside clinic	Skill assessment		
	Lecture, small	Written/ Viva		
	group discussion	voce		
	Bedside clinic	Skill assessment		
08.30 to 9.30	Lecture, Small	Skill assessment/		
	group discussion	Viva voce		
	Lecture, Small	Skill assessment/		
	group discussion	Viva voce		
	g. 2 a a			
08.30 to 9.30	Bedside clinic	Skill assessment		
		NA 111 / 12 / 12		
	Lecture	Written/ Viva		
		voce		
08.30 to 9.30	Lecture	Written/ Viva		
		voce		
	Lecture	Written/ Viva		
		voce		

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce
	Lecture, Small group discussion	Written/ Viva voce
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce
08.30 to 9.30	Lecture, Small group	Written/ Viva voce

Suggested Assessment	Number required	Vertical	Horizontal	
method	to certify P	Integration	Integration	
Written/ Viva voce	1	Dermatology,Ve	1	
written/ viva voce		nereology & Leprosy		
Written/ Viva voce		Deprosy		
Written/ Viva voce				
Written/ Viva voce				
Written/ Viva voce		Dermatology, Venereology & Leprosy		
Written/ Viva voce		Deprosy		
Written		Dermatology, Venereology & Leprosy		
Written/ Viva voce		Dermatology,		
THE TOTAL TOTAL		Venereology & Leprosy		
Written/ Viva voce				
Written/ Viva voce				

Written/ Viva voce			
XX /XX			
Written/ Viva voce			
	_		
Written/ Viva voce	Dermatology,		
	Venereology &		
	Leprosy		
Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce	Dermatology,		
	Venereology &		
	, energatagy es		
Written/ Viva voce			
Written/ Viva voce			
XX / X			
Written/ Viva voce			
Written/ Viva voce			
Wilten/ Viva voce			
Written/ Viva voce			
Wilten/ Viva voce			
W (W.			
Written/ Viva voce			
	<u> </u>		
Skill Assessment	Dermatology,		
	Venereology &		
	Leprosy		
Skill Assessment			
Skill Assessment	 		
DAIII ASSESSIIICIII			

Written/ Viva voce Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce			
Written/ Viva voce	Dermatology, Venereology & Leprosy	Microbiology	
Written/ Viva voce	2000)		
Written/ Viva voce			
Written/ Viva voce	Dermatology, Venereology & Leprosy		
Skill Assessment	Dermatology, Venereology & Leprosy		
Bedside clinics	,		